Press Releases

Aurora BioPharma to Present at the 2017 BIO International Convention

Cambridge, MA, June 16, 2017 -- Aurora BioPharma, Inc., a clinical stage biotechnology company developing genetically reprogrammed T Cell therapy to treat Solid and Liquid tumors, announced today that company CEO and President, Robert Brooks, will present at the 2017 BIO International Convention taking place at the San Diego Convention Center June 19 – 22.

​About BIO International Convention

The BIO International Convention attracts industry leaders who gather to discover new partnerships in the areas of cell therapy, drug discovery, genomics, nanotechnology, biofuels, and biomanufacturing. The event serves as an opportunity to network with over 16,000 representatives from over 3,100 companies and institutions. The event attracts C-level executives, investors, physicians, and researchers in the fields of biotechnology and biopharmaceuticals who take part in more than 35,000 face-to-face meetings.

​About Aurora BioPharma

Aurora is leading in the development of Chimeric Antigen Receptor (CAR) T therapy, with an extensive clinical pipeline. Osteosarcoma is the most common type of bone cancer in Children and Adolescents. A completed Phase I/IIa trial in 19 Sarcoma (16 Osteosarcoma) patients was completed, Aurora's CAR T agent AU-101 met its endpoints of safety, with strong signs of tumor killing efficacy, and long term survivors. Glioblastoma is the most common and deadliest form of brain cancer. Aurora's CAR T agent AU105 showed in a completed Phase I/IIa clinical trial in 16 Glioblastoma patients, safety, tumor killing efficacy, and double the median historic overall survival. Aurora is planning a randomized multi-site Phase II trial of AU105 in Early Diagnosed Glioblastoma, and a Phase I/II trial in Recurrent Glioblastoma with intracranial injection. Aurora is planning a Phase II trial of its CAR T Cell therapy AU105 in Osteosarcoma.

For more information, please visit or follow us:


Forward-Looking Statements

The electronic message you received is confidential and may be legally privileged or otherwise protected from disclosure. If you are not the intended recipient, please call or email the sender and delete this message and any attachment from your system; you must not copy or disclose the contents of this message or any attachment to any other person.

This is not an offer or a solicitation of an offer to purchase or sell any security. Statements in this message that are not based on historical or current facts, including without limitation statements such as the words "anticipates," "believes," "may," "continues," "estimates," "expects," and "will" constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward- looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Although Aurora BioPharma believes that expectations conveyed by the forward-looking statements are reasonable based on the information available to it on the date such statements were made, no assurances can be given as to the future results, approvals or achievements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements, and should assume the Company has no obligation to update forward-looking statements except as otherwise required by applicable law.

For media inquiries, please contact:

Candace Cobos

Aurora BioPharma, Inc.

Tel: (617) 674-7718 - Fax: (617) 674-7701

SOURCE Aurora BioPharma, Inc.